✨
AI Summary & Key Takeaways
AI Insight⚡ TL;DR(Too Long; Didn't Read)
In conclusion, we recommend levetiracetam as the first line treatment for EPC, which is mostly refractory to classical antiepileptic drugs
📌 3 Key Takeaways
🎯
Objective & Hypothesis:An 82-year-old, right-handed male patient was admitted to the emergency room because of continuous rhythmic clonic movements of the right forearm and hand.
📊
Key Findings & Data:He was diagnosed with epilepsia partialis continua (EPC) and treated successfully with levetiracetam.
💡
Conclusion & Impact:In conclusion, we recommend levetiracetam as the first line treatment for EPC, which is mostly refractory to classical antiepileptic drugs
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
An 82-year-old, right-handed male patient was admitted to the emergency room because of continuous rhythmic clonic movements of the right forearm and hand. He was diagnosed with epilepsia partialis continua (EPC) and treated successfully with levetiracetam. In conclusion, we recommend levetiracetam as the first line treatment for EPC, which is mostly refractory to classical antiepileptic drugs
🔖
Cite This Article
YÖN, M. İ., ULUSOY, E. K., BİLEN, Ş., YÖN, M. E. E. (2016). Levetiracetam May be the First Choice for Managing Epilepsia Partialis Continua Related to Ischemic Stroke. Erciyes Medical Journal, Cilt: 38 - Sayı: 4, 157–158. https://ajindex.com/articles/203580